Latest news with #CTx-1301
Business Insider
09-08-2025
- Business
- Business Insider
Cingulate CEO tells Roth COO departure has no meaningful impact on CTx-1301
After Cingulate (CING) announced the termination of Laurie Myers as COO, Roth Capital caught up with Cingulate Therapeutics' CEO Shane Schaffer to get additional clarity on the 'sudden termination.' The firm's conversation with the CEO suggests the COO's departure has no meaningful impact on the company's near-term strategy or long-term outlook, including the timelines for CTx-1301 FDA approval expected in mid-2026. Following the talks with the CEO, the firm reiterates its Buy rating and $11 price target on Cingulate shares. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Business Insider
19-05-2025
- Business
- Business Insider
Cingulate price target lowered to $11 from $12 at Roth Capital
Roth Capital analyst Boobalan Pachaiyappan lowered the firm's price target on Cingulate (CING) to $11 from $12 and keeps a Buy rating on the shares post the Q1 report. The firm says its discussions with management further bolstered its conviction for CTx-1301 application filing, which it expects to occur in Q3. Roth's base case assumes CTx-1301 FDA approval by Q4 of 2026 and launch by the first half of 2027. Confident Investing Starts Here:
